Food Supplementation With Diuripres for Blood Pressure Modulation in Subjects With High-Normal Blood Pressure
NCT05167747 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2024-02-01
Summary
Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, reaching the 31% of deaths in 2012. CVDs represent also the major cause of disability in developed countries and has been estimated that their growing burden could lead to a global increase in loss of disability-adjusted life years (DALY), from a loss of 85 million DALYs of 1990 to a loss of \~ 150 million DALYs in 2020, becoming a major cause of no psychic responsible for lost productivity.
Several risk factors contribute to the aetiology and development of CVD. These factors have been traditionally stratified into modifiable risk factors through the lifestyle changes or by taking a pharmacologic treatment (e.g. hypertension, smoking, diabetes mellitus, hypercholesterolemia) and not modifiable risk factors (age, male sex and family history). Essential hypertension is the most common modifiable risk factor in the general population, with a prevalence in Western Countries -including Italy- ranging between about 25-45%.
Given the large prevalence of the disease of the general population, hypertension is responsible for the vast majority of CVD in individuals with different CV risk profiles, despite the availability of effective and well tolerated antihypertensive therapies. In this regard, several reports have shown that hypertensive patients often present additional CV and metabolic risk factors, mostly hypercholesterolemia, hypertriglyceridemia, metabolic syndrome and diabetes, which further contribute to increase the individual risk of developing hypertension-related complications, including stroke, end-stage renal disease, congestive heart failure, and CVD death. The concomitant presence of hypertension and dyslipidaemia is also responsible for the objective difficulty in achieving the recommended therapeutic targets for BP and cholesterol levels in a setting of clinical practice.
Several pharmacological and non-pharmacological interventions have been proposed for ameliorating the relatively low rates of control of hypertension. Among these, an extensive use of nutrients and food supplements has been shown to provide favourable effects in the management and control of high-normal blood pressure (BP) (or pre-hypertension), that increases the risk of developing hypertension, cardiovascular diseases, and renal failure.
Conditions
- High-Normal Blood Pressure
Interventions
- DIETARY_SUPPLEMENT
-
Dietary Supplement
Dietary supplement formulated with magnesium, standardized extract of orthosiphon, standardized extract of hawthorn and standardized extract of hibiscus. Each tablet contains: 0.1 g magnesium, 0.25 g standardized extract of orthosiphon (Orthosiphon stamineus Benth), 0.16 standardized extract of hawthorn (Crataegus curvisepala Lind.) and 0.08 g standardized extract of hibiscus (Hibiscus sabdariffa L.). Oral administration: 2 tablets/day at evening meal
- OTHER
-
Placebo
Oral administration: 2 tablets/day at evening meal
Sponsors & Collaborators
-
University of Bologna
lead OTHER
Principal Investigators
-
Arrigo F. Cicero, MD · S. Orsola-Malpighi University Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-09-01
- Primary Completion
- 2022-03-25
- Completion
- 2022-03-25
Countries
- Italy
Study Locations
More Related Trials
-
Dietary Nitrate on Blood Pressure and Cardiovascular Disease Risk Factors
NCT03478631 ·Status: UNKNOWN ·Phase: PHASE3
-
Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)
NCT04040634 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Effect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients
NCT06169241 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects
NCT01974570 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Hypertension
NCT00000484 ·Status: COMPLETED ·Phase: PHASE3
-
Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate
NCT03234361 ·Status: COMPLETED ·Phase: PHASE2
-
Diet, ExerCIse and carDiovascular hEalth (DECIDE) - Salt Reduction Strategies for the Elderly in Nursing Homes in China
NCT03290716 ·Status: COMPLETED ·Phase: NA
-
Blood Pressure Reduction in Heart Failure
NCT01255475 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effects of Nitrate in Vegetables on Blood Pressure in Subjects With Prehypertension
NCT02916615 ·Status: COMPLETED ·Phase: NA
-
Hypertension Prevention in Pre-Hypertensive Individuals
NCT00970931 ·Status: COMPLETED ·Phase: PHASE3
-
Phosphate in Blood Pressure Regulation
NCT02822131 ·Status: COMPLETED ·Phase: NA
-
Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
NCT00387621 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Management of Hypertension and Multiple Risk Factors to Enhance Cardiovascular Health
NCT02972619 ·Status: UNKNOWN ·Phase: NA
-
A Study to Investigate the Effect of a Nitric Oxide Supplementation on Pre- and Mildly Hypertensive Adults
NCT02679248 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage
NCT00687206 ·Status: COMPLETED ·Phase: PHASE4
-
ABG+/GarlACE Effects on Cardiovascular Risk Factors in Subjects With Grade I Hypertension
NCT06264622 ·Status: RECRUITING ·Phase: NA
-
Dietary Nitrates and Vascular Function in Patients With Peripheral Artery Disease
NCT01983826 ·Status: COMPLETED ·Phase: NA
-
Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in Hypertension
NCT03592667 ·Status: UNKNOWN ·Phase: PHASE4
-
Long-term of Remote Ischemic Preconditioning and Mindfulness in Patients With Mild Hypertension
NCT04753840 ·Status: RECRUITING ·Phase: NA
-
Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo
NCT01900171 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Citrulline and Arginine Supplementation on the Post-exercise Hypotension (PEH)
NCT03378596 ·Status: UNKNOWN ·Phase: NA
-
Effects of Antihypertensive Drug Treatment on Brain Blood Flow, Cognition, and Regulation of Nervous System in Older Adults With Hypertension.
NCT06287580 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Acute Effect of Agiotensin-(1-7) in Healthy and Hypertensive Subjects
NCT03001271 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
B-type Natriuretic Peptide (BNP) in Human Hypertension
NCT00953472 ·Status: TERMINATED ·Phase: PHASE1
-
The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients
NCT02563405 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3